PM
CTMX icon

Prosight Management’s CytomX Therapeutics CTMX Stock Holding History

Prosight Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-564,800
Closed -$1.8M – 46
2025
Q3 		$1.8M Sell
564,800
-2,952,313
-84% -$6.65M 0.43% 34
2025
Q2 		$7.98M Sell
3,517,113
-412,895
-11% -$666K 1.95% 17
2025
Q1 		$2.5M Buy
3,930,008
+25,008
+0.6% +$19.4K 0.82% 27
2024
Q4 		$4.02M Buy
3,905,000
+882,891
+29% +$950K 1.13% 23
2024
Q3 		$3.57M Buy
+3,022,109
New +$3.84M 0.9% 30

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.66B AUM 340.85% 1-Year Est. Return